Indivior (INDV): insider & executive buying
Indivior · Health Care · ref. ETF XLV · price $35.42
In short — 1 insider bought Indivior over ~6 months (2 buys, total $108k, latest Aug 27, 26). Public Form 4 data, informative (not a performance signal).
Are Indivior's executives buying their own shares? Here are the disclosed insider buys over the last 6 months — a transparency data point, not an outperformance signal.
📈 1-year price
$35.42+44.3% over range
Oct 14, 25low $24.09 · high $41.83Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 1 analysts
Latest insider buys on Indivior
| Date | Insider | Role | Shares | Amount |
|---|---|---|---|---|
| Aug 27, 26 | Anderson Woodrow D | Chief Accounting Officer | 1,500 | $54k |
| Aug 5, 26 | Anderson Woodrow D | Chief Accounting Officer | 1,500 | $54k |
⚠️ Open-market buys reported to the SEC (Form 4). Transparency data, not advice nor an outperformance signal (our backtests show no reliable edge).
Frequently asked questions
Have Indivior's executives bought shares recently?
1 Indivior insider(s) bought $108k over ~6 months (latest Aug 27, 26). A buy shows confidence, but our backtests show no performance edge.
Is insider buying a good signal for INDV?
It's useful transparency data, but NOT a performance guarantee: our historical tests show no reliable edge from following insider buys. Cross-check with fundamentals and analyst views.
Where does this data come from?
From Form 4 filings with the SEC (mandatory for officers and 10%+ holders), aggregated and refreshed regularly.
💬 A question about Indivior? The JPI assistant answers using our backtest data.
Keep exploring Indivior